×

OncoMed Management to Present at Two Upcoming Investment Conferences

REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:

Jefferies 2016 Healthcare Conference
Sunil Patel, OncoMed’s Chief Financial Officer, Senior Vice President, Corporate Development and Finance, will provide a corporate update on Thursday, June 9, 2016 at 3:00 p.m. EDT in New York.

JMP Securities Life Sciences Conference 2016
Sunil Patel and John Lewicki, PhD, OncoMed’s Executive Vice President of Research and Development, will participate in a fireside chat on Tuesday, June 21, 2016 at 10:00 a.m. EDT in New York.

A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).

Additional information can be found at the company's website: www.oncomed.com.

Contact:
Media & Investors
OncoMed Pharmaceuticals
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
michelle.corral@oncomed.com
(650) 995-8373

Source:OncoMed Pharmaceuticals, Inc.